Search Results

25 results

  1. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, STPOST 16

    Comparison of in vitro cytotoxicity and genotoxicity of condensates derived from electronic-cigarettes and reference combustible cigarette

    DOSHI U.; GARDNER W.; LEE K.M.
    Altria Client Services LLC, Richmond, VA, U.S.A.
    In recent years, electronic nicotine delivery systems (ENDS) including electronic cigarettes (e-cigarettes) have emerged as potential reduced-risk alternatives to conventional cigarettes for adult smokers. The U.S. Food and Drug Administration (FDA),...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 36

    Use of ex vivo precision-cut lung slices as a screening tool for potential respiratory toxicity of e-liquids

    BEHRSING H.P.(1); SHEEHAN D.(1); AMIN K.(2); LEE K.M.(3); OLDHAM M.(4); RAABE H.(1)
    (1) Institute for In Vitro Sciences, Inc., Gaithersburg, MD, U.S.A.; (2) University of Minnesota, Minneapolis, MN, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) former Altria Client Services employee
    The Family Smoking Prevention and Tobacco Control Act gave the FDA regulatory authority over next generation tobacco products (NGTP) such as e-vapor products. E-vapor product liquids contain a variety of ingredient combinations that should be...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 38

    In vitro cytotoxicity and genotoxicity of representative e-liquid flavor mixtures

    DOSHI U.; ZHANG J.; KUMAR A.; LEE K.M.
    Altria Client Services LLC, Richmond, VA 23219, U.S.A.
    Flavor compounds “generally recognized as safe” for oral consumption are commonly used in inhalable e-vapor products for which insufficient safety data exists. The hazard characterization of each flavor and various flavor mixtures is resource and...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in...
  7. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 022 (also presented at CORESTA SSPT2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); HOENG J.(2); PEITSCH M.(2); SKOWRONEK A.(3); LEE K.M.(1)
    (1) Altria Client Services, Richmond, VA, USA; (2) Philip Morris International, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, USA
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion...
  8. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 067

    Characterization of smokeless tobacco products extracted with different solvents for in vitro testing

    ZHANG JINGJIE (1); DOSHI U.(1); THAIKOOTTATHIL J.(1); LEE K.M.(1); WOLZ R.L.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) Enthalpy Analytical, Richmond, VA, USA
    Unlike cigarettes, there are no standardized methods available for preparing extracts from smokeless tobacco (SLT) products for in vitro toxicological evaluation. Methods are available for Harmful and Potentially Harmful constituents (HPHCs)...
  9. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 103

    Preclinical testing of flavors in e-vapor products - Part 1: Selection of representative flavor mixtures for toxicological evaluations using a structural grouping approach

    EHMAN K.D.(1); LANGSTON T.B.(1); KUMAR A.(1); LEE K.M.(1); SCIUSCIO D.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Neuchâtel, Switzerland
    A variety of flavor ingredients are used in potentially reduced-risk tobacco or nicotine products, including e-vapor products. For this work, the ingredients were initially evaluated for quality and purity, which included assessment of food grade and...
  10. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 104

    Preclinical testing of flavors in e-vapor products - Part 2: Preparation and stability characterization of representative flavor mixtures

    SMITH C.R.(1); MILLER J.H. IV(1); SHAH N.(1); KUMAR A.(1); LEE K.M.(1); FRAUENDORFER F.(2); GUY P.(2); DIANA P.(2); GLABASNIA A.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Neuchâtel, Switzerland
    GLP guidelines require the characterization of test articles for preclinical biological studies to ensure the identity and composition are consistent from batch to batch and throughout the testing period. For e-vapor products, this would suggest that...